Arbutus Biopharma Corpora...
3.19
-0.16 (-4.78%)
At close: Jan 14, 2025, 3:59 PM
3.20
0.52%
After-hours Jan 14, 2025, 05:18 PM EST
undefined%
Bid 3.2
Market Cap 603.53M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.44
PE Ratio (ttm) -7.24
Forward PE n/a
Analyst Strong Buy
Ask 3.4
Volume 593,896
Avg. Volume (20D) 907,170
Open 3.38
Previous Close 3.35
Day's Range 3.18 - 3.38
52-Week Range 2.21 - 4.72
Beta undefined

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2007
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ABUS

Analyst Forecast

According to 4 analyst ratings, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $5, which is an increase of 56.99% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Arbutus Biopharma Corporation is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $2.21M, reflecting a 3.03% YoY growth and earnings per share of -0.12, making a 0.00% YoY.
2 months ago · Source
+0.28%
Barinthus Biotherapeutics shares are trading lower... Unlock content with Pro Subscription
9 months ago · Source
+15.87%
Arbutus Biopharma shares are trading higher amid circulation of documents from an Arbutus/Genevant vs Moderna patent infringement lawsuit.